Instructions on whether larotrectinib (Vitaika) must be taken continuously once taken

Larotrectinib is an oral small molecule targeted drug mainly used to treat patients with solid tumors carrying NTRK gene fusions. Its mechanism of action is to selectively inhibit TRK receptor kinase activity and block abnormal signaling pathways, thereby inhibiting tumor cell proliferation and survival. Due to the characteristic of NTRK fusion driving tumor growth, the anti-tumor effect of larotrectinib relies on continuous inhibition of TRK signaling, so the continuity of medication is of great significance to the efficacy.

Clinical studies have shown that for patients who initially took larotrectinib, long-term continued use can significantly prolong progression-free survival (PFS) and overall response rate (ORR). The tumor burden of most patients remains stable or further shrinks during continued medication, but once medication is discontinued, some patients may experience tumor recurrence or progression. Therefore, from an efficacy perspective, it is generally recommended to continue taking larotrectinib until disease progression, intolerable adverse reactions occur, or a physician assesses that the treatment regimen needs to be adjusted.

However, continued medication is not an absolute requirement. For a small number of patients with complete remission, it may be clinically considered to gradually evaluate whether the drug can be discontinued or the medication interval can be extended based on the condition and doctor's recommendations, but this needs to be done under strict monitoring and regular imaging evaluation. There is currently a lack of data on the maintenance of efficacy after large-scale long-term discontinuation, so discontinuation decisions must be cautious and guided by professional oncologists.

In practical applications, patients should undergo regular hematology, liver and kidney function and imaging monitoring while taking larotrectinib to ensure the efficacy and safety of the drug. Any planned discontinuation of medication or dose adjustment should be carried out under the guidance of a physician, and individualized decisions should be made based on changes in the condition and tolerance. Overall, continuous administration of larotrectinib is crucial to maintaining efficacy, but the specific course of treatment should be based on the patient's actual condition and clinical assessment to determine the optimal plan.

Reference link:https://www.drugs.com